Kevin Ong's research while affiliated with Armadale Health Service and other places

Publications (31)

Article
Full-text available
Neural plasticity—the ability to alter a neuronal response to environmental stimuli—is an important factor in learning and memory. Short-term synaptic plasticity and long-term synaptic plasticity, including long-term potentiation and long-term depression, are the most-characterized models of learning and memory at the molecular and cellular level....
Article
Full-text available
Alzheimer’s disease (AD) is a degenerative brain disorder and is the most common form of dementia. Minimally invasive approaches are required that combine biomarkers to identify individuals who are at risk of developing mild cognitive impairment (MCI) and AD, to appropriately target clinical trials for therapeutic discovery as well as lifestyle str...
Article
Background: Alzheimer's disease (AD) is characterised by impairment of memory. However specific types of memory related symptoms (MRS) may be more pertinent to AD. This study evaluated the predictive accuracy of different MRS for AD in memory clinic patients, and the predictive utility of different MRS and numbers of MRS for hypoglycaemic patterns...
Article
Full-text available
Aims: Test the robustness of a linear regression transformation of semiquantitative values from different Aβ tracers into a single continuous scale. Study Design: Retrospective analysis. Place and Duration of Study: PET imaging data acquired in Melbourne and Perth, Australia, between August 2006 and May 2014. Methodology: Aβ imaging in 633 particip...
Article
Background We assessed the clinical utility of β-amyloid (Aβ) imaging with 18F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory ov...
Article
Information on 54 patients were retrospectively collected to compare the presentation trends of cognitive disorders in those of non-English speaking background (NESB) to English speak-ing background (ESB) attending an Australian memory clinic that extensively uses fluorode-oxyglucose positron emission tomography (FDG PET) in the diagnosis of cognit...
Data
Information on 54 patients were retrospectively collected to compare the presentation trends of cognitive disorders in those of non-English speaking background (NESB) to English speak-ing background (ESB) attending an Australian memory clinic that extensively uses fluorode-oxyglucose positron emission tomography (FDG PET) in the diagnosis of cognit...
Data
Full-text available
Figure S1 showing the relationship between WMH and nonmemory scores in MCI subjects with low and high Aβ. There was a significant correlation between WMH and nonmemory scores in MCI subjects with high Aβ in the brain, but the association was not present in the low Aβ subgroup. naMCI, nonamnestic mild cognitive impairment.
Article
Full-text available
Introduction 18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impairment (MCI). Methods Forty-five MCI participants were evaluated. A neocortical standardized uptake value ratio threshold ≥ 1....
Article
Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted...
Article
Amyloid imaging with (18)F-labelled radiotracers will allow widespread use of this technique, facilitating research, diagnosis and therapeutic development for Alzheimer's disease (AD). The purpose of this analysis was to compare data on cortical Aβ deposition in subjects who had undergone both (11)C-PiB (PiB) and (18)F-florbetaben (FBB) PET imaging...
Article
Full-text available
Amyloid imaging with (18)F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using (18)F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal loba...

Citations

... Recent genetic studies, including genotyping in specific diseases [60], have highlighted the role of oxidative stress as an inducer of neurodegeneration, causing toxicity and promoting cell death [61,62]. Learning and memory are possible only because of the neural plasticity; genetic and environmental factors are involved both in pathological processes and in slowing or preventing cognitive de-cline; molecular biomarkers can contribute to the diagnosis of neurodegeneration and guide pharmacological interventions [63]. Here we aimed to open new avenues in the studies of the influence of specific genes on the benefits of non-pharmacological therapies. ...
... Following neural damage, direct repair mechanism neuroregeneration may help restore original or close to original brain functions in cellular and tissue levels [16]. Furthermore, overall neural activities can be maintained by the ability of the nervous system to recruit other components by reorganizing its structure, connections, and/or functions (that is neuroplasticity [17]). The capacity of neuroplasticity is bounded by resilience, which is the ability to be flexible and adaptive in response to harmful challenges [18]. ...
... There is evidence that examining buccal cells for biomarkers in AD might be a promising approach. Apart from amyloid-beta and Tau, markers of interest in buccal cells are telomeres [69][70][71][72], DNA content and structure [73][74][75] or combined biomarker panels [76], showing the ability to differentiate between healthy control subjects and patients suffering from MCI and AD. Different studies were able to confirm correlations between buccal cell-derived biomarkers and clinical AD. ...
... A meta-analysis conducted by Kishi et al. [134] indicated that memantine improved symptoms of FTD slightly better than placebo and might be of therapeutic benefit for these patients. We have previously reported a case of early FTD wherein the individual benefited from memantine use [135]. Studies on the use of memantine in DLB and PDD patients demonstrated its significant impact on cognitive and motor [152] Rajan et al. [153] Milosevic et al. [154] Picconi et al. [155] Jang et al. [156] Siuda et al. [157] Nardone et al. [158] Antipsychotic [160] Koss et al. [162] Youdim [163] Zhu et al. [164] AD ...
... Each tracer has different pharmacokinetic, binding affinities and specific reference regions that are reflected in their distinct standardised uptake value ratio (SUVR) cut-off to distinguish high Aβ (A+) from low Aβ (A−). Therefore, to place the standardised uptake value ratio (SUVR) of the F-18 amyloid tracers on a single continuous scale, the SUVRs were linearly transformed into PiB-like SUVR units called the Before the Centiloid Kernel Transformation (BeCKeT) [25]. Brain Aβ positivity was then determined based on an SUVR/BeCKeT cut-off value of 1.4 [26]. ...
... 18 F-labeled amyloid tracers florbetaben (Barthel et al. 2011), florbetapir ) and flutemetamol (Nelissen et al. 2009; Curtis Clinical practicality of amyloid tracers is to detect amyloid in patients with mild cognitive impairment (MCI) or subjective neurological symptoms to predict progression to AD. Among MCI patients positive for amyloid imaged with florbetaben, 83% progressed to AD, suggesting a high predictive accuracy (Ong et al. 2015). In the effort to find effective treatments for AD, amyloid-PET is a non-invasive method utilized for monitoring response to amyloid-targeted therapies. ...
... Non-memory tests are generally less predictive of dementia in those with more education. Neuropsychological screening tools like the mini-mental state examination are cultural and language biased even with the use of an interpreter [45]. Efficacy can be limited by ceiling effects and variability in subject performance over time. ...
... For example, a recent correlation of in vivo PiB retention to post-mortem amyloid plaque load showed a strong positive correlation. 139 However, it remains likely PiB may be more suited to ruling out AD, 138 due to its high sensitivity. ...
... 155 Binding is lower in the parietal cortex and temporal cortex and largely absent from the sensorimotor cortex and cerebellar gray matter. 17,[152][153][154]156,157 Florbetaben has a smaller dynamic range than 11 C-PIB 150 and also differs in that it is more likely to stain discrete amyloid plaques than diffuse amyloid. All 18 F-labeled amyloid markers appear to have higher white matter uptake compared to 11 C-PIB. ...
... Florbetaben is now under phase II and phase III clinical trials. 11,17,134,151,153,154 Of note, florbetaben was recently acquired from Bayer HealthCare Pharmaceuticals, Inc. by Piramal Healthcare, which plans to submit for FDA approval before the end of 2012. This marker is rapidly metabolized in the liver by O-dialkylation and N-demethylation to polar metabolites. ...